Moderna mRNA vaccine almost halves the risk of skin cancer returning
Moderna and Merck reported a 42% reduction in melanoma recurrence or death for an investigational vaccine added to Keytruda in a late-stage trial.
TL;DR
- Moderna and Merck said their personalized mRNA vaccine, used with Keytruda, reduced the risk of melanoma recurrence or death by 42% in a late-stage trial.
- The result was reported by Nature, CNBC and Reuters, which described the combination as investigational and the outcome as a trial result.
- The reports do not establish regulatory approval, long-term durability, or how the result applies beyond the studied patient group.
Moderna and Merck reported that their personalized mRNA vaccine, combined with Merck’s Keytruda, reduced the risk of melanoma recurrence or death by 42% in a late-stage trial. Nature reported the finding on October 23, and Reuters separately reported the companies’ announcement. [1] [2]
The evidence described in these reports concerns the combination regimen compared with Keytruda alone. It is a clinical-trial result for an investigational vaccine, not a report of regulatory authorization or routine availability. [1] [2] [3]
CNBC also covered the data and the market reaction, while focusing on the companies’ presentation of the result. The coverage identifies the finding as a potentially important development but does not replace the underlying trial record. [3]
The cited coverage does not settle the durability of benefit over longer follow-up, the precise scope of eligible patients, or the timing of any regulatory submission. Those questions remain open based on the reports reviewed here. [1] [2] [3]
Why it matters
The result adds a late-stage clinical data point to personalized mRNA cancer vaccines and the established checkpoint-inhibitor treatment context. Its commercial and clinical significance will depend on fuller trial data, follow-up and regulatory review.
Editor's note
Cross-checked Nature, Reuters and CNBC. Reported 42% relative risk reduction is stated as reported; the cited coverage does not establish approval or long-term outcomes.